On the public citation graph
Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer
0 signed · 64 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-mopenalex-snapshot
Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule
inferredcites →https://doi.org/10.1002/1097-0142(19860201)57:3<567::aid-cncr2820570328>3.0.co;2-yopenalex-snapshot
Does more intense palliative treatment improve overall survival in metastatic breast cancer patients?
inferredcites →https://doi.org/10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-zopenalex-snapshot
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma
inferredcites →https://doi.org/10.1002/cpt1977222234openalex-snapshot
Biliary disposition of adriamycin
inferredcites →https://doi.org/10.1007/bf00254604openalex-snapshot
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia
inferredcites →https://doi.org/10.1007/bf00262581openalex-snapshot
Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients
inferredcites →https://doi.org/10.1007/bf00446222openalex-snapshot
Early-phase pharmacokinetics of doxorubicin in non-hodgkin lymphoma patients
inferredcites →https://doi.org/10.1007/bf00609693openalex-snapshot
Pharmacokinetic study of IV infusions of adriamycin
inferredcites →https://doi.org/10.1016/0277-5379(82)90072-4openalex-snapshot
Pharmacokinetics of adriamycin in patients with breast cancer: Correlation between pharmacokinetic parameters and clinical short-term response
inferredcites →https://doi.org/10.1016/0277-5379(83)90085-8openalex-snapshot
Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer
inferredcites →https://doi.org/10.1016/0277-5379(89)90007-2openalex-snapshot
Pharmacokinetics of weekly low dose doxorubicin
inferredcites →https://doi.org/10.1016/0277-5379(89)90135-1openalex-snapshot
Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy
inferredcites →https://doi.org/10.1016/0277-5379(89)90264-2openalex-snapshot
Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients
inferredcites →https://doi.org/10.1016/0378-4347(87)80171-8openalex-snapshot
Estimation of doxorubicin and doxorubicinol by high-performance liquid chromatography and advanced automated sample processor
inferredcites →https://doi.org/10.1038/bjc.1987.226openalex-snapshot
A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma
inferredcites →https://doi.org/10.1038/bjc.1987.295openalex-snapshot
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer
inferredcites →https://doi.org/10.1038/clpt.1987.92openalex-snapshot
Plasma and cellular Adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion
inferredcites →https://doi.org/10.1038/clpt.1989.39openalex-snapshot
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin
inferredcites →https://doi.org/10.1089/cdd.1987.4.191openalex-snapshot
Continuous Infusion or Intravenous Bolus: What Is the Rationale for Doxorubicin Administration?
inferredcites →https://doi.org/10.1097/00007691-198901000-00002openalex-snapshot
Clinical Pharmacology of Continuous Infusion Doxorubicin
inferredcites →https://doi.org/10.1097/00007691-198907000-00002openalex-snapshot
Alteration in Doxorubicin and Doxorubicinol Plasma Concentrations with Repeated Courses to Patients
inferredcites →https://doi.org/10.1200/jco.1987.5.2.172openalex-snapshot
A phase I-II study of intensive-dose adriamycin for advanced breast cancer.
inferredcites →https://doi.org/10.1200/jco.1987.5.2.178openalex-snapshot
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study.
inferredcites →https://doi.org/10.1248/bpb1978.4.879openalex-snapshot
A pharmacokinetic analysis program (multi) for microcomputer.
inferredcites →https://doi.org/10.3329/jom.v12i2.8427openalex-snapshot
A Young Male with Progressive Pallor
inferredcites →https://doi.org/10.7326/0003-4819-96-2-133openalex-snapshot
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4781335openalex-extracted
The Abl1 Tyrosine Kinase and p53 are Key Players in Doxorubicin-Induced Cardiomyopathy and Their Cell Death Signaling Differs in Atrial and Ventricular Cardiomyocytes
inferred← citeshttps://doi.org/10.1002/bmc.3181openalex-snapshot
Quantitative study of cellular heterogeneity in doxorubicin uptake and its pharmacological effect on cancer cells
inferred← citeshttps://doi.org/10.1002/elps.1150191624openalex-snapshot
Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis
inferred← citeshttps://doi.org/10.1007/978-90-481-9704-0_5openalex-snapshot
Anthracyclines and Anthracenediones
inferred← citeshttps://doi.org/10.1007/bf00685876openalex-snapshot
Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit
inferred← citeshttps://doi.org/10.1007/bf03190013openalex-snapshot
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane® and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC)
inferred← citeshttps://doi.org/10.1007/s00210-023-02886-8openalex-snapshot
Comparison of bolus administration and short-term infusion versus long-term infusion of doxorubicin in terms of cardiotoxicity and efficacy
inferred← citeshttps://doi.org/10.1007/s002800050644openalex-snapshot
In vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds
inferred← citeshttps://doi.org/10.1016/0959-8049(92)90447-aopenalex-snapshot
Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life
inferred← citeshttps://doi.org/10.1016/0959-8049(96)00177-3openalex-snapshot
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
inferred← citeshttps://doi.org/10.1016/j.ajpath.2026.08.007openalex-snapshot
Immunologically Active Cardiac Fibroblasts Expressing Major Histocompatibility Complex-II Promote Doxorubicin Cardiotoxicity
inferred← citeshttps://doi.org/10.1016/j.breast.2017.04.001openalex-snapshot
The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy
inferred← citeshttps://doi.org/10.1016/j.ejca.2008.11.019openalex-snapshot
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer
inferred← citeshttps://doi.org/10.1016/j.ejpb.2012.12.012openalex-snapshot
Drug release kinetics, cell uptake, and tumor toxicity of hybrid VVVVVVKK peptide-assembled polylactide nanoparticles
inferred← citeshttps://doi.org/10.1016/j.ejpb.2020.06.004openalex-snapshot
A physiologically-based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release
inferred← citeshttps://doi.org/10.1016/j.xphs.2019.05.029openalex-snapshot
Understanding the Influence of Nanocarrier-Mediated Brain Delivery on Therapeutic Performance Through Pharmacokinetic-Pharmacodynamic Modeling
inferred← citeshttps://doi.org/10.1016/s1055-3207(18)30393-4openalex-snapshot
Isolated Liver Perfusion for Liver Metastases: Pharmacokinetic Advantage?
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.6b00880openalex-snapshot
Doxorubicin Delivery into Tumor Cells by Stable Cavitation without Contrast Agents
inferred← citeshttps://doi.org/10.1023/a:1006213815195openalex-snapshot
Weekly epirubicin plus lonidamine in advanced breast carcinoma
inferred← citeshttps://doi.org/10.1023/a:1008324329562openalex-snapshot
Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer
inferred← citeshttps://doi.org/10.1038/bjc.1996.668openalex-snapshot
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer
inferred← citeshttps://doi.org/10.1039/b817511jopenalex-snapshot
Synthesis and in vitro activity of ROMP-based polymer nanoparticles
inferred← citeshttps://doi.org/10.1080/17425247.2020.1772749openalex-snapshot
Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin
inferred← citeshttps://doi.org/10.1084/jem.20151665openalex-snapshot
Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
inferred← citeshttps://doi.org/10.1097/00001813-200301000-00008openalex-snapshot
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma
inferred← citeshttps://doi.org/10.1097/cad.0b013e328035f863openalex-snapshot
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study
inferred← citeshttps://doi.org/10.11575/prism/25293openalex-snapshot
Characterization of the In Vivo Consequences of Salicylate Co-Administration on the Efficacy of Topoisomerase II Poison-Based Chemotherapy in a Model of Human Breast Cancer
inferred← citeshttps://doi.org/10.1159/000065716openalex-snapshot
Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast Carcinoma
inferred← citeshttps://doi.org/10.1172/jci.insight.124092openalex-snapshot
Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer
inferred← citeshttps://doi.org/10.1186/s12967-024-05623-8openalex-snapshot
The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes
inferred← citeshttps://doi.org/10.1200/jco.1999.17.7.2293copenalex-snapshot
Doxorubicin Cardiotoxicity: Growing Importance
inferred← citeshttps://doi.org/10.1371/journal.pone.0129233openalex-snapshot
Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome
inferred← citeshttps://doi.org/10.2165/00003495-199447020-00002openalex-snapshot
Anthracycline Antibiotics in Cancer Therapy
inferred← citeshttps://doi.org/10.3233/bd-2001-14104openalex-snapshot
Dosage Parameters in Chemotherapy of Breast Cancer
inferred← citeshttps://doi.org/10.3389/ftox.2025.1644119openalex-snapshot
Integral approach to organelle profiling in human iPSC-derived cardiomyocytes enhances in vitro cardiac safety classification of known cardiotoxic compounds
inferred← citeshttps://doi.org/10.4155/tde.10.9openalex-snapshot
Nucleic Acid Therapeutics: Concepts for Targeted Delivery to Solid Tumors
inferred← citeshttps://doi.org/10.53846/goediss-702openalex-snapshot
Pharmakokinetik von Doxorubicin: Populationsvariabilität und Einfluss von genetischen Polymorphismen in Membran-Trasportproteinen
inferred← citeshttps://doi.org/10.70675/e4fb4ae8z8f4bz4102z8154z52fb69dc4af4openalex-snapshot
Nanoparticules de resveratrol/PLAGA pour réduire la toxicité notamment hépatique de la doxorubicine
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.